Overview

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

Status:
Completed
Trial end date:
2008-02-15
Target enrollment:
Participant gender:
Summary
This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Flurbiprofen
Midazolam
Rosiglitazone